

**GENETIC PROFILING OF K13 ARTEMISININ-RESISTANT *Plasmodium falciparum* AMONG PATIENTS ATTENDING HEALTHCARE FACILITIES  
IN OTA, NIGERIA**

**OYEGBADE, SAMUEL ADENIYI  
(22PCQ02462)**

**B.Sc. Microbiology, Adekunle Ajasin University, Akungba Akoko, Ondo State**

**AUGUST, 2024**

**GENETIC PROFILING OF K13 ARTEMISININ-RESISTANT *Plasmodium falciparum* AMONG PATIENTS ATTENDING HEALTHCARE FACILITIES IN OTA NIGERIA**

**BY**

**OYEGBADE, SAMUEL ADENIYI  
(22PCQ02462)**

**B.Sc. Microbiology, Adekunle Ajasin University, Akungba Akoko, Ondo State.**

**A DISSERTATION SUBMITTED TO THE SCHOOL OF POSTGRADUATE STUDIES IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF MASTER OF SCIENCE (M.Sc) DEGREE IN MICROBIOLOGY IN THE DEPARTMENT OF BIOLOGICAL SCIENCES, COLLEGE OF SCIENCE AND TECHNOLOGY, COVENANT UNIVERSITY, OTA, OGUN STATE, NIGERIA**

**AUGUST, 2024**

## **ACCEPTANCE**

This is to attest that this dissertation is accepted in partial fulfilment of the requirements for the award of the degree of Master of Sciences in Microbiology in the Department of Biological Sciences, College of Science and Technology, Covenant University, Ota, Nigeria.

**Miss Adefunke F. Oyinloye**  
**(Secretary, School of Postgraduate Studies)**

**Signature and Date**

**Prof. Akan B. Williams**  
**(Dean, School of Postgraduate Studies)**

**Signature and Date**

## **DECLARATION**

**I, OYEGBADE, SAMUEL ADENIYI (22PCQ02462)** declare that this research was carried out by me under the supervision of Dr Paul A. Akinduti of the Department of Biological Sciences, College of Science and Technology, Covenant University, Ota, Nigeria. I attest that the dissertation has not been presented either wholly or partially for the award of any degree elsewhere. All sources of data and scholarly information used in this dissertation are duly acknowledged.

**OYEGBADE, SAMUEL ADENIYI**

**Signature and Date**

## **CERTIFICATION**

We certify that this dissertation titled **GENETIC PROFILING OF K13 ARTEMISININ-RESISTANT *Plasmodium falciparum* AMONG PATIENTS ATTENDING HEALTHCARE FACILITIES IN OTA NIGERIA**” is an original research work carried out by **OYEGBADE, SAMUEL ADENIYI (22PCQ02462)** in the Department of Biological Sciences, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria under the supervision of Dr. Paul A. Akinduti. We have examined and found this work acceptable as part of the requirements for the award of Master of Science in Microbiology.

**Dr. Paul A. Akinduti**  
(Supervisor)

**Signature and Date**

**Dr. Isaac O. Ayanda**  
(Head of Department)

**Signature and Date**

**Prof. Segun I. Oyedeji**  
(External Examiner)

**Signature and Date**

**Prof. Akan B. Williams**  
(Dean, School of Postgraduate Studies)

**Signature and Date**

## **DEDICATION**

Dedicated to the Almighty God for His grace, wisdom, and sufficient strength

## **ACKNOWLEDGEMENT**

All thanks to Almighty God for granting me the grace and strength to complete this research work successfully. My sincere appreciation goes to my supervisor Dr. Paul Akinduti for his patience, love, and prompt guidance throughout the duration of this research work. His dedication and passion for this work not only provided me with an avenue for a quality research output but also enhanced my capacity and inquisitiveness for learning and research.

I am also grateful to my Head of Department (HOD), Dr. Ayanda, Isaac Opeyemi for his advice and fatherly counsel, Dr. Oluwafemi Oyewole for his valuable input and contributions, every faculty, and staff, as well as to the entire Covenant University, for their immeasurable impact on my life throughout my studentship at Covenant University.

My appreciation goes to Covenant Applied Informatics and Communication, Africa Centre of Excellence (CApIC-ACE), who provided the funding for my studentship and the successful completion of this research work, your generosity and impact are indeed applaudable.

I want to thank my friends and colleagues who in diverse ways supported me throughout my academic endeavors at Covenant University; Mr David Oladejo, Mr. Bode Onile -ere, Mr. Jide, Mr. Toba, Adedotun Arogundade, Emmanuel Mameh, Daniel Balogun, Victoria-Grace Aririguzho, Temitope Oluwaseyi, Zeedi Kwarpo, Samuel Esther among others.

I want to thank my family and family friends; Nifesimi Adebayo, Mr. Thomas Oyegbade, Mrs. Eunice Olushey, Mr. Oloruntoba Ajibero, Mr. Deji Olowolafe, Bro Yemi Ajibero, Pastor Adewoyin, Pastor Segun and Household of Faith brethren for their prayers and full support towards the successful completion of this research.

# TABLE OF CONTENTS

CONTENTS	PAGES
<b>TITLE PAGE</b>	<b>i</b>
<b>COVER PAGE</b>	<b>ii</b>
<b>ACCEPTANCE</b>	<b>iii</b>
<b>DECLARATION</b>	<b>iv</b>
<b>CERTIFICATION</b>	<b>v</b>
<b>DEDICATION</b>	<b>vi</b>
<b>AKNOWLEDGEMENTS</b>	<b>vii</b>
<b>TABLE OF CONTENTS</b>	<b>viii</b>
<b>LIST OF TABLES</b>	<b>xi</b>
<b>LIST OF FIGURES</b>	<b>xii</b>
<b>ABSTRACT</b>	<b>xiii</b>
<b>CHAPTER ONE:</b>	
<b>INTRODUCTION</b>	<b>1</b>
1.1 Background of the Study	1
1.2 Statement of Research Problem	2
1.3 Justification of Study	2
1.4 Aim and Objectives	2
<b>CHAPTER TWO</b>	<b>3</b>
<b>LITERATURE REVIEW</b>	<b>3</b>
2.1 Epidemiology of Malaria Disease	3
2.2 Overview of <i>Plasmodium falciparum</i>	4
2.3 Lifecycle of <i>Plasmodium falciparum</i> enhancing <i>PfK13</i> emergence	4
2.4 Artemisinin	7
2.5 The Activation of Artemisinin for Parasite Clearance	9
2.5.1 Role of Iron in activating artemisinin	9
2.5.2 Role of Heme in activating artemisinin	10
2.6 Potential Targets of Artemisinin	10
2.6.1. Heme	10
2.6.2. PfATP6	11
2.6.3. TCTP	12
2.6.4 Alkylation of Promiscuous protein	12
2.7 Artemisinin Combination Therapy	14
2.7.1 Artemisinins and oxidative stress	16



2.8 Antimalaria Resistance	16
2.8.1 Artemisinin Resistance	17
2.8.2 Genetic Structure of <i>PfK13</i>	19
2.8.3 K13 Gene and Cytosome	20
2.8.4 Partial Loss of Role of Mutant K13	20
2.9 Cross-Resistance Extension of Artemisinin with Other Antimalarials	22
2.9.1 Risk of Worldwide Spread of Artemisinin Resistance	23
2.9.2 Potential Modifications of Artemisinin-Based Treatments for Increased Efficacy	25
2.9.2.1 Prolonged treatment course	25
2.9.2.2 The alternate use of different antimalarial regimens	26
2.9.2.3 Triple artemisinin-based combination therapy	28
2.9.2.4 ACT in combination with malaria vaccine in MDA efforts to eliminate malaria	28
<b>CHAPTER THREE</b>	30
<b>MATERIALS AND METHODS</b>	30
3.1 Materials	30
3.1.1 Equipment and materials	30
3.1.2 Reagents	30
3.2 Methodology	30
3.2.1 Ethical Approval	30
3.2.2 Inclusion criteria	30
3.2.3 Exclusion criteria	30
3.2.4 Study site	30
3.2.5 Sample size	31
3.2.6 Sample collection	31
3.3 Blood for Malaria Microscopy	31
3.3.1. Thick and thin blood smear preparation	31
3.3.2 Parasitemia level	32
3.4 Giemsa Staining of Malaria Blood Films	32
3.4.1. Procedure: for 3% slow method	32
3.5 PCR genotyping	32
3.5.1 DNA Extraction	32
3.5.1 <i>Pf</i> kelch 13 PCR Amplification	33
3.5.2 Primary PCR Amplification	33
3.5.3 Nested PCR Amplification	33
3.6 Gel Electrophoresis	33

3.7 Sanger Gene Sequencing	38
3.9 Data Analysis	38
<b>CHAPTER FOUR</b>	39
<b>RESULTS</b>	39
4.1 Sample Analysis	39
4.2 Prevalence of malaria infection among the population	39
4.3 Relationship between age distributions and malaria infection	41
4.4 Prevalence of <i>PfK13</i> among the population	42
4.5 Parasitemia distribution by gender	43
4.6 Parasitemia level Among the Males	44
4.7 Parasitemia level Among the Females	45
4.8 Parasitemia Distribution by age and by gender	46
<b>CHAPTER FIVE</b>	51
<b>DISCUSSION</b>	51
5.1 Prevalence of Malaria Disease	51
5.2 Prevalence of <i>PfK13</i>	52
5.3 Clonal Diversity of <i>PfK13</i>	52
<b>CHAPTER SIX</b>	54
<b>CONCLUSION AND RECOMMENDATION</b>	54
<b>6.1 Conclusion</b>	54
6.2 Contribution to Knowledge	54
6.3 Recommendation	54
References	55
<b>APPENDIX</b>	74
Appendix 1: <i>Plasmodium falciparum</i> infected red blood cells under the microscope	74
Appendix 2: Simple Bar mean of parasitemia by age group	75
Appendix 3: Ethical Approval Certificate	76
Appendix 4: Centre for Learning and Resources Certificate	77

## LIST OF TABLES

<b>TABLES</b>	<b>LIST OF TABLES</b>	<b>PAGES</b>
Table 1	Artemisinin and Partner drugs	15
Table 3.1	Primer sequence of kelch 13 gene	35
Table 3.2	Primary and Nested PCR reaction mix for kelch propeller (K13) gene	36
Table 3.3	Thermal cycling primary PCR conditions for kelch propeller (K13) gene	37
Table 3.4	Thermal cycling nested PCR conditions for kelch propeller (K13) gene	38
Table 4.1	Gender demography in <i>P. falciparum</i> prevalence rate	40
Table 4.2	Age distribution in <i>P. falciparum</i> prevalence rate	41
Table 4.3	Distribution of <i>P. falciparum</i> k13 among different age groups	42

## LIST OF FIGURES

FIGURES	LIST OF FIGURES	PAGES
Figure 1	Lifecycle of <i>Plasmodium falciparum</i>	6
Figure 2	Structure of artemisinin and a derivative	8
Figure 3	A model of the mechanism of action of artemisinin	13
Figure 4	Mutations and structural representation of <i>PfK13</i>	21
Fig 4.1	Overall prevalence of Pf Malaria in the population	39
Figure 4.2	Simple Bar Mean of Parasitemia by Gender	43
Figure 4.3	Simple Scatter with Fit Line of Age by Parasitemia-Female	44
Figure 4.4	Simple Scatter with Fit Line of Age by Parasitemia-Male	45
Figure 4.5	Clustered Boxplot of Parasitemia by Age Group by Gender	46
Fig 4.6	<i>PfK13</i> genotype for gender	47
Figure 4.7:	DNA amplicon bands of <i>PfK13</i> from pf positive cases on agarose	48
Figure 4.8:	Phylogenetic diversity of the <i>Plasmodium falciparum</i> K13 genotype from Nigeria with global strains	49
Figure 4.9	Phylogenetic analysis of <i>PfK13</i> genotypes with Nigeria strains.	50

## ABSTRACT

Malaria stands out incessantly as a potential concern to public health systems in Africa, particularly with the prevalence of *Plasmodium falciparum* characterized with resistance to artemisinin alongside kelch13 (*Pfkelch13*) gene alterations. This study aimed to evaluate the prevalence of *Plasmodium falciparum* infection, genomic profiling and clonal diversity of *PfKelch13* among patients attending selected health facilities in Ota, Nigeria. 479 patients with severe *P. falciparum* infection were engaged and their demographic status were collected. The blood samples from the patients were examined for *P. falciparum* infective stages and enumerated for parasitemia using Microscopy. DNA was isolated from high parasitemia *P. falciparum* samples and genotyped for *Pfkelch13* using Primary and Nested PCR assays and examined with 1% agarose gel electrophoresis. Identified *PfK13* samples were sequenced using Sanger sequencing method and further analyzed for clonal diversity. Overall, *P. falciparum* malaria identified by microscopy was 265 (55.33%). Significant prevalence of 33.61% was observed among 11-20 years age group, and 29.44% rates among male based on gender demography ( $p < 0.05$ ). Parasitemia levels ( $>200$  parasites per 100uL) were higher among male than female populations and increases among age groups (0-10 and 11-20 years). Of 10.57% *PfKelch13* genotypes, higher rates of 5.66% were observed among the male compared to female. Pf strains encoded with K13 from Nigerian population clustered with other global strains identified in UK, France, China and Kuwait. *PfK13* strains obtained from this study clustered separately with strains previously reported in African countries including Ghana, Kenya and Nigeria. There is evidence of *Pfkelch13* strains in Ota Southwest Nigeria having clonal relatedness with *P. falciparum* K13 markers Y494H and C580Y (Ghana), A578S (Kenya) and A675V (Nigeria). There is need for urgent genosurveillance and public oriented preventive strategies to curb possible spread of *PfK13* strains and identification of *PfK13* markers for diagnosis and drug target.

**Keywords:** Artemisinin-resistant *Plasmodium falciparum*, *pfkelch 13*, mutation, resistance, parasitemia